Atomoxetine
- Generic Name
- Atomoxetine
- Brand Names
- Strattera
- Drug Type
- Small Molecule
- Chemical Formula
- C17H21NO
- CAS Number
- 83015-26-3
- Unique Ingredient Identifier
- ASW034S0B8
- Background
Atomoxetine is a selective norepinephrine (NE) reuptake inhibitor used for the treatment of attention deficit hyperactivity disorder (ADHD). Also known as the marketed product Strattera, atomoxetine is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve developmentally inappropriate symptoms associat...
- Indication
Atomoxetine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adults.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
- Associated Therapies
- -
Cortical Excitability: Phenotype and Biomarker in Attention-deficit, Hyperactivity Disorder (ADHD) Therapy
- Conditions
- Interventions
- First Posted Date
- 2011-04-07
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- University of Cincinnati
- Target Recruit Count
- 120
- Registration Number
- NCT01330693
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
🇺🇸Cincinnati Children's Hospital, Cincinnati, Ohio, United States
Efficacy of Atomoxetine for ADHD in Adolescents and Young Adults With SUD
- Conditions
- Interventions
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2013-03-05
- Lead Sponsor
- Massachusetts General Hospital
- Registration Number
- NCT01207622
- Locations
- 🇺🇸
Massachusetts General Hospital, Cambridge, Massachusetts, United States
A Bioequivalence (BE) Study in Healthy Subjects
- First Posted Date
- 2010-08-09
- Last Posted Date
- 2011-10-27
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 42
- Registration Number
- NCT01177943
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Fukuoka, Japan
Interventions for Children With Attention and Reading Disorders
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2017-04-11
- Target Recruit Count
- 222
- Registration Number
- NCT01133847
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸University of Texas Health Science Center, Houston, Texas, United States
Event-related Potentials in Management of Children With Attention-deficit/Hyperactivity Disorder
- First Posted Date
- 2010-05-26
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Far Eastern Memorial Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT01130467
- Locations
- 🇨🇳
Children Hospital, National Taiwan University Hospital, Taipei, Taiwan
A Study in Attention Deficit Hyperactivity Disorder in Children and Adolescents
- Conditions
- Interventions
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2012-11-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 23
- Registration Number
- NCT01127646
- Locations
- 🇸🇪
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Uppsala, Sweden
Concerta and Strattera on the Executive Function in Attention Deficit Hyperactivity Disorder (ADHD) Children
- Conditions
- Interventions
- First Posted Date
- 2010-02-09
- Last Posted Date
- 2011-07-22
- Lead Sponsor
- Peking University
- Target Recruit Count
- 262
- Registration Number
- NCT01065259
- Locations
- 🇨🇳
Peking University Sixth Hospital, Beijing, Beijing, China
Therapeutic Drug Monitoring in Child and Adolescent Psychiatry
- Conditions
- Interventions
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Medical University of Vienna
- Target Recruit Count
- 200
- Registration Number
- NCT01057329
- Locations
- 🇦🇹
Medical University of Vienna, Vienna, Austria
A Long Term Follow-Up Study for Asian Adult Patients With Attention Deficit Hyperactivity Disorder
- First Posted Date
- 2009-09-01
- Last Posted Date
- 2012-12-12
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 211
- Registration Number
- NCT00969618
- Locations
- 🇯🇵
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, Japan
Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder
- Conditions
- Interventions
- First Posted Date
- 2009-08-19
- Last Posted Date
- 2012-09-11
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 391
- Registration Number
- NCT00962104
- Locations
- 🇨🇳
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tao-Yuan, Taiwan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.